Chemistry and Theranostic applications of radiolabeled nanoparticles for cardiovascular, oncological, and pulmonary research

Current Topics in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 470-478

  Guo, Yunjun ^a   Aweda, Tolulope ^a   Black, Kvar C L ^a   Liu, Yongjian ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiology; Lung; Nanoparticles; Oncology; Radiolabeling; Theranostics

Indexed keywords

BROMINE 76; COPPER 64; DOXORUBICIN; FLUORINE 18; GALLIUM 67; GALLIUM 68; INDIUM 111; IODINE 123; IODINE 125; NANOPARTICLE; TECHNETIUM 99M; YTTRIUM 86; ZIRCONIUM;

BIOCOMPATIBILITY; BIODEGRADABILITY; BREAST CANCER; CANCER THERAPY; CARDIOVASCULAR SYSTEM; CIRCULATION; COLON CARCINOMA; CORRELATION ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; ISOTOPE LABELING; LUNG; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLATIONAL RESEARCH; XENOGRAFT;

ANIMALS; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; HUMANS; ISOTOPE LABELING; LUNG DISEASES; NANOCAPSULES; NEOPLASMS;

EID: 84878781354     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313040007     Document Type: Review

References (82)

1. Welch, M. J.; Hawker, C. J.; Wooley, K. L., The advantages ofnanoparticles for PET. J. Nucl. Med., 2009, 50, 1743-1746.
2. Elsabahy, M.; Wooley, K. L., Design of polymeric nanoparticlesfor biomedical delivery applications. Chem. Soc. Rev., 2012, 41,2545-2561.
3. Huang, H. C.; Barua, S.; Sharma, G.; Dey, S. K.; Rege, K., Inorganic nanoparticles for cancer imaging and therapy. J. Control.Release, 2011, 155, 344-357.
4. Heneweer, C.; Gendy, S. E.; Penate-Medina, O., Liposomes andinorganic nanoparticles for drug delivery and cancer imaging. Ther.Deliv., 2012, 3, 645-656.
5. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C., Self-assembledtargeted nanoparticles: evolution of technologies and bench tobedside translation. Acc. Chem. Res., 2011, 44, 1123-1134
6. Kamaly, N.; Xiao, Z.; Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C., Targeted polymeric therapeutic nanoparticles:design, development and clinical translation. Chem. Soc. Rev.,2012, 41, 2971-3010.
7. Wang, A. Z.; Langer, R.; Farokhzad, O. C., Nanoparticle deliveryof cancer drugs. Ann. Rev. Med., 2012, 63, 185-198.
8. Dreaden, E. C.; Alkilany, A. M.; Huang, X.; Murphy, C. J.; El-Sayed, M. A., The golden age: gold nanoparticles for biomedicine.Chem. Soc. Rev., 2012, 41, 2740-2779.
9. Yoo, D.; Lee, J. H.; Shin, T. H.; Cheon, J., Theranostic magneticnanoparticles. Acc. Chem. Res., 2011, 44, 863-874.
10. Jokerst, J. V.; Gambhir, S. S., Molecular imaging with theranosticnanoparticles. Acc. Chem. Res., 2011, 44, 1050-1060.
11. Fernandez-Fernandez, A.; Manchanda, R.; McGoron, A. J., Theranostic applications of nanomaterials in cancer: drug delivery,image-guided therapy, and multifunctional platforms. Appl.Biochem. Biotechnol., 2011, 165, 1628-1651.
12. Bouzigues, C.; Gacoin, T.; Alexandrou, A., Biological applicationsof rare-earth based nanoparticles. ACS nano, 2011,5, 8488-8505.
13. Choi, K. Y.; Liu, G.; Lee, S.; Chen, X., Theranostic nanoplatformsfor simultaneous cancer imaging and therapy: current approachesand future perspectives. Nanoscale, 2012,4, 330-342.
14. Lee, D. E.; Koo, H.; Sun, I. C.; Ryu, J. H.; Kim, K.; Kwon, I. C., Multifunctional nanoparticles for multimodal imaging andtheragnosis. Chem. Soc. Rev., 2012, 41, 2656-2672.
15. Manzoor, A. A.; Lindner, L. H.; Landon, C. D.; Park, J. Y.; Simnick, A. J.; Dreher, M. R.; Das, S.; Hanna, G.; Park, W.; Chilkoti, A.; Koning, G. A.; Ten Hagen, T. L.; Needham, D.; Dewhirst, M. W., Overcoming Limitations in Nanoparticle DrugDelivery: Triggered, Intravascular Release to Improve DrugPenetration into Tumors. Cancer Res, 2012,72, 5566-5575.
16. Baber, O.; Jang, M.; Barber, D.; Powers, K., Amorphous silicacoatings on magnetic nanoparticles enhance stability and reducetoxicity to in vitro BEAS-2B cells. Inhal Toxicol, 2011,23, 532-543.
17. Mattheolabakis, G.; Rigas, B.; Constantinides, P. P., Nanodeliverystrategies in cancer chemotherapy: biological rationale andpharmaceutical perspectives. Nanomedicine, 2012,7, 1577-1590.
18. Glaus, C.; Rossin, R.; Welch, M. J.; Bao, G., In vivo evaluation of(64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MRimaging agent. Bioconjug. Chem., 2010, 21, 715-722.
19. Xia, Y.; Lim, B., Nanotechnology: Beyond the confines oftemplates. Nature, 2010, 467, 923-924.
20. Xia, Y.; Li, W.; Cobley, C. M.; Chen, J.; Xia, X.; Zhang, Q.; Yang, M.; Cho, E. C.; Brown, P. K., Gold nanocages: from synthesis totheranostic applications. Acc. Chem. Res., 2011, 44, 914-924.
21. Liu, Y.; Welch, M. J., Nanoparticles labeled with positron emittingnuclides: advantages, methods, and applications. Bioconjug. Chem.,2012, 23, 671-682.
22. Guo, Y.; Ferdani, R.; Anderson, C. J., Preparation and biologicalevaluation of (64)Cu labeled tyr(3)-octreotate using a phosphonicAcid-based cross-bridged macrocyclic chelator. Bioconjug. Chem.,2012, 23, 1470-1477.
23. McCarthy, D. W.; Shefer, R. E.; Klinkowstein, R. E.; Bass, L. A.; Margeneau, W. H.; Cutler, C. S.; Anderson, C. J.; Welch, M. J., Efficient production of high specific activity 64Cu using abiomedical cyclotron. Nucl. Med. Biol., 1997, 24, 35-43.
24. Anderson, C. J.; Ferdani, R., Copper-64 radiopharmaceuticals forPET imaging of cancer: advances in preclinical and clinicalresearch. Cancer Biother. Radiopharm, 2009,24, 379-393.
25. http://clinicaltrials.gov/ct2/results?term=dota.
26. Wooley, K. L.; Moore, J. S.; Wu, C.; Yang, Y., Novel polymers:molecular to nanoscale order in three dimensions. Proc. Natl. Acad.Sci. U. S. A.2000,97, 11147-11148.
27. Sun, X.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M. J.; Welch, M. J.; Wooley, K. L., An assessment of the effects of shellcross-linked nanoparticle size, core composition, and surfacePEGylation on in vivo biodistribution. Biomacromolecules, 2005,6,2541-2554.
28. Xu, J.; Sun, G.; Rossin, R.; Hagooly, A.; Li, Z.; Fukukawa, K. I.; Messmore, B. W.; Moore, D. A.; Welch, M. J.; Hawker, C. J.; Wooley, K. L., Labeling of Polymer Nanostructures for MedicalImaging: Importance of crosslinking extent, spacer length, andcharge density. Macromolecules, 2007,40, 2971-2973.
29. Sun, G.; Hagooly, A.; Xu, J.; Nystrom, A. M.; Li, Z.; Rossin, R.; Moore, D. A.; Wooley, K. L.; Welch, M. J., Facile, efficientapproach to accomplish tunable chemistries and variablebiodistributions for shell cross-linked nanoparticles. Biomacromolecules, 2008, 9, 1997-2006.
30. Rossin, R.; Pan, D.; Qi, K.; Turner, J. L.; Sun, X.; Wooley, K. L.; Welch, M. J., 64Cu-labeled folate-conjugated shell cross-linkednanoparticles for tumor imaging and radiotherapy: synthesis,radiolabeling, and biologic evaluation. J. Nucl. Med., 2005, 46,1210-1218.
31. Zeng, D.; Lee, N. S.; Liu, Y.; Zhou, D.; Dence, C. S.; Wooley, K.L.; Katzenellenbogen, J. A.; Welch, M. J., 64Cu Core-labelednanoparticles with high specific activity via metal-free clickchemistry. ACS Nano, 2012,6, 5209-5219.
32. Pressly, E. D.; Rossin, R.; Hagooly, A.; Fukukawa, K.; Messmore, B. W.; Welch, M. J.; Wooley, K. L.; Lamm, M. S.; Hule, R. A.; Pochan, D. J.; Hawker, C. J., Structural effects on thebiodistribution and positron emission tomography (PET) imagingof well-defined 64Cu-labeled nanoparticles comprised ofamphiphilic block graft copolymers. Biomacromolecules, 2007,8,3126-3134.
33. Shokeen, M.; Pressly, E. D.; Hagooly, A.; Zheleznyak, A.; Ramos, N.; Fiamengo, A. L.; Welch, M. J.; Hawker, C. J.; Anderson, C. J., Evaluation of multivalent, functional polymeric nanoparticles forimaging applications. ACS Nano, 2011,5, 738-747.
34. Liu, Y.; Pressly, E. D.; Abendschein, D. R.; Hawker, C. J.; Woodard, G. E.; Woodard, P. K.; Welch, M. J., Targetingangiogenesis using a C-type atrial natriuretic factor-conjugatednanoprobe and PET. J. Nucl. Med.2012,52, 1956-1963.
35. Lu, W.; Xiong, C.; Zhang, G.; Huang, Q.; Zhang, R.; Zhang, J. Z.; Li, C., Targeted photothermal ablation of murine melanomas withmelanocyte-stimulating hormone analog-conjugated hollow goldnanospheres. Clin. Cancer Res., 2009,15, 876-886.
36. Chen, J.; Glaus, C.; Laforest, R.; Zhang, Q.; Yang, M.; Gidding, M.; Welch, M. J.; Xia, Y., Gold nanocages as photothermaltransducers for cancer treatment. Small, 2010,6, 811-817.
37. Wang, Y.; Liu, Y.; Luehmann, H.; Xia, X.; Brown, P.; Jarreau, C.; Welch, M.; Xia, Y., Evaluating the pharmacokinetics and in vivocancer targeting capability of Au nanocages by positron emissiontomography imaging. ACS Nano, 2012,6, 5880-5888.
38. Xie, H.; Diagaradjane, P.; Deorukhkar, A. A.; Goins, B.; Bao, A.; Phillips, W. T.; Wang, Z.; Schwartz, J.; Krishnan, S., Integrinalphavbeta3-targeted gold nanoshells augment tumor vasculaturespecificimaging and therapy. Int. J. Nanomedicine, 2011,6, 259-269.
39. Gupta, A. K.; Gupta, M., Synthesis and surface engineering of ironoxide nanoparticles for biomedical applications. Biomaterials,2005,26, 3995-4021.
40. Mornet, S.; Vasseur, S.; Grasset, F.; Duguet, E., Magneticnanoparticle design for medical diagnosis and therapy. J. Mater.Chem., 2004,14, 2161-2175.
41. Li, Z.; Wei, L.; Gao, M. Y.; Lei, H., One-pot reaction to synthesizebiocompatible magnetite nanoparticles. Adv. Mater.2005,17, 1001.
42. Hiergeist, R.; Andra, W.; Buske, N.; Hergt, R.; Hilger, I.; Richter, U.; Kaiser, W., Application of magnetite ferrofluids forhyperthermia. J. Magn. Magn. Mater., 1999,201, 420-422.
43. Lu, A. H.; Salabas, E. L.; Schuth, F., Magnetic nanoparticles:Synthesis, protection, functionalization, and application. Angew.Chem. Int. Ed. Engl., 2007,46, 1222-1244.
44. Yang, X.; Hong, H.; Grailer, J. J.; Rowland, I. J.; Javadi, A.; Hurley, S. A.; Xiao, Y.; Yang, Y.; Zhang, Y.; Nickles, R. J.; Cai, W.; Steeber, D. A.; Gong, S., cRGD-functionalized, DOXconjugated,and 64Cu-labeled superparamagnetic iron oxidenanoparticles for targeted anticancer drug delivery and PET/MRimaging. Biomaterials, 2011,32, 4151-4160.
45. Devaraj, N. K.; Keliher, E. J.; Thurber, G. M.; Nahrendorf, M.; Weissleder, R., 18F labeled nanoparticles for in vivo PET-CTimaging. Bioconjug. Chem., 2009, 20, 397-401.
46. Nahrendorf, M.; Keliher, E.; Marinelli, B.; Leuschner, F.; Robbins, C. S.; Gerszten, R. E.; Pittet, M. J.; Swirski, F. K.; Weissleder, R., Detection of macrophages in aortic aneurysms by nanoparticlepositron emission tomography-computed tomography. Arterioscler.Thromb. Vasc. Biol., 2011, 31, 750-757.
47. Liu, Q.; Sun, Y.; Li, C.; Zhou, J.; Li, C.; Yang, T.; Zhang, X.; Yi, T.; Wu, D.; Li, F., 18F-Labeled magnetic-upconversionnanophosphors via rare-Earth cation-assisted ligand assembly. ACSNano, 2011,5, 3146-3157.
48. Zhou, J.; Yu, M.; Sun, Y.; Zhang, X.; Zhu, X.; Wu, Z.; Wu, D.; Li, F., Fluorine-18-labeled Gd3+/Yb3+/Er3+ co-doped NaYF4nanophosphors for multimodality PET/MR/UCL imaging. Biomaterials, 2011,32, 1148-1156.
49. Martin, R.; Menchon, C.; Apostolova, N.; Victor, V. M.; Alvaro, M.; Herance, J. R.; Garcia, H., Nano-Jewels in Biology. Gold andPlatinum on Diamond Nanoparticles as Antioxidant SystemsAgainst Cellular Oxidative Stress. ACS Nano, 2010,4, 6957-6965.
50. Rojas, S.; Gispert, J. D.; Martin, R.; Abad, S.; Menchon, C.; Pareto, D.; Victor, V. M.; Alvaro, M.; Garcia, H.; Herance, J. R., Biodistribution of amino-functionalized diamond nanoparticles. Invivo studies based on 18F radionuclide emission. ACS Nano,2011,5, 5552-5559.
51. Almutairi, A.; Rossin, R.; Shokeen, M.; Hagooly, A.; Ananth, A.; Capoccia, B.; Guillaudeu, S.; Abendschein, D.; Anderson, C. J.; Welch, M. J.; Frechet, J. M., Biodegradable dendritic positronemittingnanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl. Acad. Sci. USA, 2009,106, 685-690.
52. Murthy, N.; Thng, Y. X.; Schuck, S.; Xu, M. C.; Frechet, J. M., Anovel strategy for encapsulation and release of proteins: hydrogelsand microgels with acid-labile acetal cross-linkers. J. Am. Chem.Soc.2002,124, 12398-12399.
53. Murthy, N.; Xu, M.; Schuck, S.; Kunisawa, J.; Shastri, N.; Frechet, J. M., A macromolecular delivery vehicle for protein-basedvaccines: acid-degradable protein-loaded microgels. Proc. Natl.Acad. Sci. U. S. A.2003,100, 4995-5000.
54. Liu, Y.; Ibricevic, A.; Cohen, J. A.; Cohen, J. L.; Gunsten, S. P.; Frechet, J. M.; Walter, M. J.; Welch, M. J.; Brody, S. L., Impact ofhydrogel nanoparticle size and functionalization on in vivobehavior for lung imaging and therapeutics. Mol. Pharm.2009,6,1891-1902.
55. Benezra, M.; Penate-Medina, O.; Zanzonico, P. B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S.; Wolchok, J.; Larson, S. M.; Wiesner, U.; Bradbury, M. S., Multimodal silica nanoparticles are effective cancer-targetedprobes in a model of human melanoma. J. Clin. Invest., 2011, 121,2768-80.
56. Choi, J. S.; Park, J. C.; Nah, H.; Woo, S.; Oh, J.; Kim, K. M.; Cheon, G. J.; Chang, Y.; Yoo, J.; Cheon, J., A hybrid nanoparticleprobe for dual-modality positron emission tomography andmagnetic resonance imaging. Angew. Chem. Int. Ed. Engl., 2008,47, 6259-6262.
57. Park, J. C.; Yu, M. K.; An, G. I.; Park, S. I.; Oh, J.; Kim, H. J.; Kim, J. H.; Wang, E. K.; Hong, I. H.; Ha, Y. S.; Choi, T. H.; Jeong, K. S.; Chang, Y.; Welch, M. J.; Jon, S.; Yoo, J., Facile preparationof a hybrid nanoprobe for triple-modality optical/PET/MR imaging.Small, 2010,6, 2863-2868.
58. Mcelvany, K. D.; Hopkins, K. T.; Welch, M. J., Comparison of Ge-68/Ga-68 Generator Systems for Radiopharmaceutical Production.Int. J. Appl. Radiat. Is., 1984, 35, 521-524.
59. Mcelvany, K. D.; Hopkins, K. T.; Hanrahan, T. J.; Moore, H. A.; Welch, M. J., Comparison of Ge-68/Ga-68 Generator Systems forRadiopharmaceutical Production. J. Labelled. Compd. Rad., 1982,19, 1419-1420.
60. Weiner, R. E.; Thakur, M. L., Chemistry of Gallium and IndiumRadiopharmaceuticals. In Handbook of Radiopharmaceuticals,Welch, M. J.; Redvanly, C. S., Eds. Wiley: England, 2003; p 363-399.
61. Hofman, M. S.; Beauregard, J. M.; Barber, T. W.; Neels, O. C.; Eu, P.; Hicks, R. J., 68Ga PET/CT ventilation-perfusion imaging forpulmonary embolism: a pilot study with comparison toconventional scintigraphy. J. Nucl. Med., 2011,52, 1513-1519.
62. Hohn, A.; Zimmermann, K.; Schaub, E.; Hirzel, W.; Schubiger, P.A.; Schibli, R., Production and separation of "non-standard" PETnuclides at a large cyclotron facility: the experiences at the PaulScherrer Institute in Switzerland. Q. J. Nucl. Med. Mol. Imaging.,2008, 52, 145-150.
63. Holland, J. P.; Sheh, Y.; Lewis, J. S., Standardized methods for theproduction of high specific-activity zirconium-89. Nucl. Med. Biol.,2009,36, 729-739.
64. Keliher, E. J.; Yoo, J.; Nahrendorf, M.; Lewis, J. S.; Marinelli, B.; Newton, A.; Pittet, M. J.; Weissleder, R., (89)Zr-Labeled DextranNanoparticles Allow in vivo Macrophage Imaging. Bioconjug.chem., 2011,22, 2383-2389.
65. Ruggiero, A.; Villa, C. H.; Holland, J. P.; Sprinkle, S. R.; May, C.; Lewis, J. S.; Scheinberg, D. A.; McDevitt, M. R., Imaging andtreating tumor vasculature with targeted radiolabeled carbonnanotubes. Int. J. Nanomedicine, 2010, 5, 783-802.
66. R. Dilworth J.; J. Parrott, S., The biomedical chemistry oftechnetium and rhenium. Chem. Soc. Rev., 1998, 27, 43-55.
67. Kleiter, M. M.; Yu, D.; Mohammadian, L. A.; Niehaus, N.; Spasojevic, I.; Sanders, L.; Viglianti, B. L.; Yarmolenko, P. S.; Hauck, M.; Petry, N. A.; Wong, T. Z.; Dewhirst, M. W.; Thrall, D.E., A Tracer Dose of Technetium-99m-Labeled Liposomes CanEstimate the Effect of Hyperthermia on Intratumoral DoxilExtravasation. Clin.Cancer Res., 2006,12, 6800-6807.
68. Laverman, P.; Dams, E. T. M.; Oyen, W. J. G.; Storm, G.; Koenders, E. B.; Prevost, R.; van der Meer, J. W. M.; Corstens, F.H. M.; Boerman, O. C., A Novel Method to Label Liposomes with99mTc by the Hydrazino Nicotinyl Derivative. J. Nucl. Med., 1999,40, 192-197.
69. Bao, A.; Phillips, W. T.; Goins, B.; Zheng, X.; Sabour, S.; Natarajan, M.; Ross Woolley, F.; Zavaleta, C.; Otto, R. A.,Potential use of drug carried-liposomes for cancer therapy viadirect intratumoral injection. Int. J. Pharm., 2006, 316, 162-169.
70. Torres Martin de Rosales, R.; Tavare, R.; Glaria, A.; Varma, G.; Protti, A.; Blower, P. J., 99mTc-bisphosphonate-iron oxidenanoparticle conjugates for dual-modality biomedical imaging. Bioconjug. Chem., 2011, 22, 455-465.
71. Zhang, Y.; Sun, Y.; Xu, X.; Zhu, H.; Huang, L.; Zhang, X.; Qi, Y.; Shen, Y.-M., Radiosynthesis and micro-SPECT imaging of 99mTcdendrimerpoly(amido)-amine folic acid conjugate. Bioorg. Med.Chem. Lett., 2010, 20,927-931.
72. Zhang, Y.; Sun, Y.; Xu, X.; Zhang, X.; Zhu, H.; Huang, L.; Qi, Y.; Shen, Y.-M., Synthesis, Biodistribution, and Microsingle PhotonEmission Computed Tomography (SPECT) Imaging Study ofTechnetium-99m Labeled PEGylated DendrimerPoly(amidoamine) (PAMAM) Folic Acid Conjugates. J. Med.Chem., 2010, 53, 3262-3272.
73. MacDonald, N. S.; Neely, H. H.; Wood, R. A.; Takahashi, J. M.; Wakakuwa, S. I.; Birdsall, R. L., Methods for compact cyclotronproduction of indium-111 for medical use. Int. J. Appl. Radiat. Is.,1975, 26, 631-633.
74. Umeda, I.; Tani, K.; Tsuda, K.; Kobayashi, M.; Ogata, M.; Kimura, S.; Yoshimoto, M.; Kojima, S.; Moribe, K.; Yamamoto, K.; Moriyama, N.; Fujii, H., High resolution SPECT imaging forvisualization of intratumoral heterogeneity using a SPECT/CTscanner dedicated for small animal imaging. Ann. Nucl. Med.,2012, 26, 67-76.
75. DeNardo, S. J.; DeNardo, G. L.; Natarajan, A.; Miers, L. A.; Foreman, A. R.; Gruettner, C.; Adamson, G. N.; Ivkov, R., Thermal Dosimetry Predictive of Efficacy of 111In-ChL6Nanoparticle AMF-Induced Thermoablative Therapy for HumanBreast Cancer in Mice. J. Nucl. Med., 2007, 48,437-444.
76. DeNardo, S. J.; DeNardo, G. L.; Miers, L. A.; Natarajan, A.; Foreman, A. R.; Gruettner, C.; Adamson, G. N.; Ivkov, R.,Development of Tumor Targeting Bioprobes (111In-Chimeric L6Monoclonal Antibody Nanoparticles) for Alternating MagneticField Cancer Therapy. Clin. Cancer Res., 2005, 11, 7087s-7092s.
77. Harrington, K. J.; Mohammadtaghi, S.; Uster, P. S.; Glass, D.; Peters, A. M.; Vile, R. G.; Stewart, J. S. W., Effective Targeting ofSolid Tumors in Patients With Locally Advanced Cancers byRadiolabeled Pegylated Liposomes. Clin. Cancer Res., 2001, 7,243-7254.
78. Elbayoumi, T.; Torchilin, V., Tumor-Targeted Immuno-liposomesfor Delivery of Chemotherapeutics and Diagnostics. J. Pharm.Innov.2008,3, 51-58.
79. Hong, S. Y.; Tobias, G.; Al-Jamal, K. T.; Ballesteros, B.; Ali-Boucetta, H.; Lozano-Perez, S.; Nellist, P. D.; Sim, R. B.; Finucane, C.; Mather, S. J.; Green, M. L. H.; Kostarelos, K.; Davis, B. G., Filled and glycosylated carbon nanotubes for in vivoradioemitter localization and imaging. Nat. Mater., 2010, 9, 485-490.
80. Jang, B.; Park, S.; Kang, S. H.; Kim, J. K.; Kim, S.-K.; Kim, I.-H.; Choi, Y., Gold nanorods for target selective SPECT/CT imagingand photothermal therapy in vivo. Quant. Imaging Med. Surg.,2012, 2, 1-11.
81. Kim, Y.-H.; Jeon, J.; Hong, S. H.; Rhim, W.-K.; Lee, Y.-S.; Youn, H.; Chung, J.-K.; Lee, M. C.; Lee, D. S.; Kang, K. W.; Nam, J.-M., Tumor Targeting and Imaging Using Cyclic RGD-PEGylated GoldNanoparticle Probes with Directly Conjugated Iodine-125. Small,2011, 7, 2052-2060.
82. Madani, S. Y.; Naderi, N.; Dissanayake, O.; Tan, A.; Seifalian, A.M., A new era of cancer treatment: carbon nanotubes as drugdelivery tools Int. J. Nanomedicine, 2011, 6, 2963-2979